title: First Hodgkin cell line L428 and the CD30 antigen: their role for diagnostic and treatment of CD30-positive neoplasms.
abstract: Hodgkin's disease (HD) is a fatal disorder with the unique histologic features of few dysplastic Hodgkin- and Reed-Sternberg (HRS) cells surrounded by an abundance of nonatypical bystander cells in primary biopsies. By using the first Hodgkin cell line L428 the cytokine receptor CD30 was discovered. CD30 proved to be an excellent target for the diagnoses of CD30+ malignancies and for monoclonal antibody therapy in patients with these malignancies because of its highly restricted expression in healthy individuals. Recently, a new anti-CD30-toxin-drug-conjugate consisting of an anti-CD30 monoclonal antibody bound to the nonimmunogenic toxin auristatin E with a newly designed linker was generated.
authors.affiliation: Berlin Reference and Consultation Center for Lymphoma and Hematopathology, Pathodiagnostik Berlin, Komturstrasse 58-62, Berlin 12099, Germany.
authors.forename: Harald
authors.initials: H
authors.lastname: Stein
authors.forename: Volker
authors.initials: V
authors.lastname: Diehl
mesh_terms: D000818:Animals; D000911:Antibodies, Monoclonal / Q000494:pharmacology / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000494:pharmacology / Q000627:therapeutic use; D014408:Biomarkers, Tumor / Q000378:metabolism; D045744:Cell Line, Tumor; D049109:Cell Proliferation; D006689:Hodgkin Disease / Q000175:diagnosis / Q000188:drug therapy / Q000378:metabolism*; D006801:Humans; D017730:Ki-1 Antigen / Q000037:antagonists & inhibitors / Q000737:chemistry / Q000378:metabolism*; D019394:Ki-67 Antigen / Q000378:metabolism; D058990:Molecular Targeted Therapy
chemical_list: D000911:Antibodies, Monoclonal; D000970:Antineoplastic Agents; D014408:Biomarkers, Tumor; D017730:Ki-1 Antigen; D019394:Ki-67 Antigen
keywords: Detection of the CD30 Antigen; Establishment of the cell line L428; Hodgkin lymphoma